A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

PURPOSE: An open-label phase I/II study of single-agent obatoclax determined a maximum tolerated dose (MTD) and schedule, safety, and efficacy in older patients (≥70 yr) with untreated acute myeloid leukemia (AML). EXPERIMENTAL DESIGN: Phase I evaluated the safety of obatoclax infused for 3 hours on...

Descripción completa

Detalles Bibliográficos
Autores principales: Schimmer, Aaron D., Raza, Azra, Carter, Thomas H., Claxton, David, Erba, Harry, DeAngelo, Daniel J., Tallman, Martin S., Goard, Carolyn, Borthakur, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186779/
https://www.ncbi.nlm.nih.gov/pubmed/25285531
http://dx.doi.org/10.1371/journal.pone.0108694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186779/
https://www.ncbi.nlm.nih.gov/pubmed/25285531
http://dx.doi.org/10.1371/journal.pone.0108694

Ejemplares similares